A carregar...
Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro
Background: Metabolic associated fatty liver disease (MAFLD), characterized by hepatic lipid accumulation and fatty degeneration, is intertwined with obesity and type 2 diabetes mellitus (T2DM). Empagliflozin is a sodium-glucose cotransporter-2 inhibitor that effectively lowers blood glucose, but it...
Na minha lista:
| Publicado no: | Front Pharmacol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7854384/ https://ncbi.nlm.nih.gov/pubmed/33551821 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.622153 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|